RESEARCH TRIANGLE PARK, N.C. – November 9, 2010 – For the second consecutive year, Quintiles has received Scrip Awards Best Clinical Research Organization honors based upon judging by an independent panel of prestigious life sciences experts.

“This award recognizes the increasingly important role the CRO has in the drug development industry,” said Mike Ward, editor of Scrip Intelligence, which hosted the 6th Annual Scrip Awards ceremony held Thursday in London. “The judges described the Quintiles entry as outstanding and impressive … praising the company for providing truly global services, outstanding operational accountability and product development risk sharing.”

The Scrip Awards acknowledge excellence in the bio pharmaceutical industry; the awards ceremony was attended by more than 500 industry leaders from around the world.
Quintiles’ Paula Brown Stafford, Global Head of Clinical Development, said: “It’s a distinct honor to win the Best CRO award for the second consecutive year. I’d like to dedicate this award to Quintiles’ employees, who work so diligently to help our biopharma customers navigate risks and seize opportunities in the New Health.”

Earlier this year, Quintiles was rated the No. 1 preferred provider and perceived industry leader across all phases of clinical research, according to a survey of 150 biopharma industry decision-makers by the independent firm Industry Standard Research (ISR). Quintiles was rated No. 1 among 25 CROs in consistently meeting or exceeding customer service expectations across the board, according to ISR’s “2010 CRO Quality Benchmarking Report.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit